YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Competitiveness in Exports of Pharmaceuticals to Developed Countries: A Comparative Policy Analysis on South Korea and India

선진국으로의 의약품 수출 경쟁력: 한국과 인도를 대상으로 한 정책비교분석 연구

  • Yun, Su-Jin (Graduated School of Clinical Pharmacy, Sungkyunkwan University) ;
  • Cho, Eun (Department of Preventive Medicine, College of Medicine & Institute of Health Services Research, Yonsei University)
  • 윤수진 (성균관대학교 임상약학대학원 보건사회약학과) ;
  • 조은 (연세대학교 의과대학 예방의학교실 & 연세대학교 보건정책 관리연구소)
  • Received : 2012.03.05
  • Accepted : 2012.03.22
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Local pharmaceutical companies in Korea, which have grown focusing on domestic markets, have recently faced difficulties such as market saturation, price control policies and market-opening pressures by FTA. It seems to be an urgent issue for them to export pharmaceuticals to developed countries comprising the greater part of the global pharmaceutical market. Hence, this research was conducted to investigate and benchmark the strategies employed by India industry for the successful access to the global pharmaceutical markets. Drug policies as well as their influences on pharmaceutical market changes between India and Korea for the last 40 years have been searched and the differences have been comparatively analyzed. The pharmaceutical industry of India has the following strengths: low costs; experienced labor pool; excellent reverse-engineering skills; powerful IT; marketing capability; and established distribution network. After 2000, consolidations, M&A and alliances with domestic and multinational companies have been sharply increased in the industry of India. Indian companies unfolding both competition and cooperation with multinational corporations currently move up the value-added chain, and this enthusiastic strategy should be learned by local pharmaceutical companies.

Keywords

References

  1. 정재훈 : 의약분업 이후 제약기업의 경제지표 분석. 성균관대학교. 석사 (2011).
  2. Smith, B. D. : The future of pharma. Part 2 Co-evolving industry (2011).
  3. 한국보건산업진흥원 : 글로벌 제약회사의 환경변화 (2010).
  4. Docteur, E. : Pharmaceutical pricing policies in a global market. OECD Health Policy Studies, Paris (2007).
  5. Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G. and Laing, R. : Differences in external price referencing in europe: a descriptive overview. Health Policy 104, 50 (2012).
  6. Malhotra, P. : Impact of TRIPS in India- An Access to Medicines Perspectives. Part 1. Influence of global forces on access to medicines (2010).
  7. Scherer, F. M. : The pharmaceutical industry--prices and progress. N. Engl. J. Med. 351, 927 (2004).
  8. Smith, B. D. : The future of pharma. Part 1. A stalling industry. (2011).
  9. IMS Health Data: Global Pharma Forecast Pack (2010).
  10. 연세대학교 : 국내 의약품 선진시장 진출 방안을 위한 워크샵. 서울 (2011).
  11. Garattini, L. and Tediosi, F. : A comparative analysis of generics markets in five European countries. Health Policy 51, 149 (2000).
  12. Department of Pharmaceuticals: Annual Report, Government of India (2009-2010).
  13. Infodrive India. India Export Import. Available at: http://www.infodriveindia.com/export-import/trade-statistics/topproduct. aspx. Accessed August 11 (2011).
  14. Business Maps of India. Indian Pharmaceutical Industry. Available at: http://business.mapsofindia.com/pharmaceutical. Accessed Feb 2 (2012).
  15. Greene, W. : The Emergence of India's Pharmaceutical Industry and Implications for the U.S. Generic Drug Market. Office of Economics working paper No.2007-05-A, U.S. International Trade Commission (2007).
  16. 한국의약품수출입협회. Available at: http://www.kpta.or.kr/export/export_03.asp. Accessed August 18 (2011).
  17. Kim, H. J., Chung, W. and Lee, S. G. : Lessons from Korea's pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care. Health Policy 68, 267 (2004).
  18. Malhotra, P. and Lofgren, H. : India's pharmaceutical industry: hype or high tech take-off? Aust. Health Rev. 28, 182 (2004).
  19. Singh, S. : Indian pharma enters the global arena. Cell. 128, 811 (2007).
  20. 강예규 : 한국의약품의 현황과 수출증대방안. 성균관대학교. 석사 (2000).
  21. 김용후 : 한미자유무역협정 추진현황과 전망. 성균관대학교. 석사 (2006).
  22. 문상호 : 보건의료정책과 거버넌스. 국정관리연구 2, 163 (2007).
  23. 박지현 : 한미FTA 속의 TRIP-Plus. 국제법학회논총 53, 85 (2008).
  24. 한국식품의약품안전청. Available at: http://www.kfda.go.kr/index. kfda?mid=56&seq=13099 Accessed Aug 14 (2011).
  25. Kripalani, M. : Pharma Karma; Tougher patent protection laws are spurring rapid growth in new drug research across India. Business Week 39, 20 (2005).
  26. 임세호 : GMP 선진화 절실 아닌 '시급'. 약업신문, 서울 (2007).
  27. IMS Health Data MIDAS: Market Prognosis (2010).
  28. Dong-A Pharmaceutical: Annual Report (2010).
  29. Ranbaxy: Annual Report (2010).
  30. The Korean Society for Microbiology and Biotechnology. 바이 오시밀러: 해결해야 할 과제. Available at: http://www.kormb.or.kr/home/kor/Newsletter/Files/.../101125_162015626.pdf Accessed August 8 (2011).
  31. Labotaroties, I. : Annual Report (2010-2011).
  32. Cadila, Z. : Annual Report (2010-2011).
  33. Aurobindo : Annual Report (2010-2011).
  34. Limited, L. : Annual Report (2009-2010).
  35. Sun Pharmaceuticals : Annual Report (2009-2010).
  36. Cipla : Annual Report (2009-2010).
  37. Dr. Reddy : Annual Report (2010-2011).
  38. 한미약품 : 2010년도 사업보고서.
  39. 유한양행 : 2010년도 사업보고서.
  40. 지식경제부 홈페이지. Available at: http://www.mke.go.kr/policy/future/future0101.jsp Accessed Feb 8 (2012).
  41. 식품의약품안전청 홈페이지. Available at: http://www.kfda.go.kr/ index.kfda?mid=56&seq=16928&cmd=v Accessed Feb 8 (2012).
  42. Datta J. More global buys by pharma cos likely. Available at: http://www.thehindubusinessline.in/2005/07/22/stories/2005072202240300.htm Accessed Aug 17 (2011).
  43. 바이오 2008을 통해 본 세계 바이오산업 동향 및 전망. 보건산업정책 Issue Report 2008-6 (2008).
  44. Malhotra, H. : Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals 39, 321 (2011).
  45. 김태억 : 바이오시밀러 산업동향과 국내기업의 진입전략. Available at: http://k2b.biz/298 Accessed Aug 15 (2011).
  46. 한국산업마케팅연구소. 바이오의약 산업동향과 바이오시밀러 비즈니스 성공전략. Available at: http://www.bioin.or.kr/board.do?num=172034&cmd=view&bid=industry Accessed July 25 (2011).
  47. 고유상 : 세계 바이오제약산업의 M&A 동향. SERI 경제포커스. 삼성경제연구소 (2007).
  48. 식품의약품안전청. 제 18호 국내개발 신약 '슈펙트캡슐' 허가. Available at: http://www.kfda.go.kr/index.kfda?mid=56&seq= 16779&cmd=v. Accessed Jan 30 (2012).
  49. 식품의약품안전청. 2011년 상반기 천연물신약 개발 활기. Available at: http://www.kfda.go.kr/index.kfda?mid=56&seq= 15568&cmd=v Accessed Aug 14 (2011).
  50. Federal Register. 75(176) (2010).
  51. Simoens, S. : Health economics of market access for biopharmaceuticals and biosimilars. Journal of Medical Economics 12, 211 (2009).